Physician profile
Brian Kim
NPI 1871532051
$9,557.91
in general payments reported to CMS, 2019-2025
24 companies · $637 in 2025
The $637 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2021: $7,402 · 2022: $294 · 2023: $528 · 2024: $302 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,445 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,445.13 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $7,274.17 | 2021-2025 | Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $385.09 | 2023-2025 | Opdivo |
| Janssen Biotech, INC. | $322.97 | 2021-2024 | Erleada, Akeega |
| Astrazeneca Pharmaceuticals Lp | $256.57 | 2023-2025 | Imfinzi, Calquence |
| Painteq LLC | $190.80 | 2021-2024 | Painteq |
| Sirtex Medical INC | $148.50 | 2019 | |
| Vertos Medical, INC. | $130.63 | 2019 | |
| Pfizer INC. | $130.13 | 2021-2022 | |
| Sobi, INC | $124.97 | 2025 | |
| Astellas Pharma Global Development | $122.74 | 2025 | Xtandi |
| Eisai INC. | $116.48 | 2019 | |
| Astellas Pharma US INC | $65.34 | 2025 | Xtandi |
| Amgen INC. | $33.85 | 2023 | Kyprolis, Blincyto |
| Davol INC. | $29.83 | 2025 | Arista |
| Morphosys, US INC. | $29.24 | 2023 | Monjuvi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $28.49 | 2022 | |
| Novartis Pharmaceuticals Corporation | $28.00 | 2023 | |
| Relievant Medsystems, INC. | $26.34 | 2022 | |
| Abbvie INC. | $26.15 | 2023 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Celgene Corporation | $20.19 | 2023 | Reblozyl |
| Telix Pharmaceuticals | $19.20 | 2025 | |
| Medtronic, INC. | $15.26 | 2024 | Intellis Adaptivestim |
| Acrotech Biopharma INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.